Bayer to accelerate drug discovery with Google Cloud's high-performance compute power
|
12 January 2023 |
NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs
|
10 January 2023 |
Recombinant adeno-associated virus (rAAV) technology pioneered by AskBio's Dr. Jude Samulski is key component of all FDA approved AAV gene therapeutics
|
20 December 2022 |
Bayer launches industry-first public database listing company's science collaborations and partnerships in the U.S.
|
09 December 2022 |
Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros
|
02 December 2022 |
Vividion Therapeutics names Jenna Goldberg as Chief Medical Officer
|
09 November 2022 |
Bayer with continued strong performance
|
08 November 2022 |
Bayer signs grant agreement to advance innovation in non-hormonal contraception
|
20 October 2022 |
Bayer supports demining in Ukraine with donation to non-profit "Fondation suisse de déminage"
|
18 August 2022 |
Bayer Consumer Health leaders propose new principles for science-led self-care
|
02 August 2022 |
Bayer to sell men's health product Nebido™ to Grünenthal
|
18 July 2022 |
Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
|
29 June 2022 |
Bayer delivers on medical innovation fueling transformation of pharma business
|
21 February 2022 |
Leaps by Bayer leads $80M Series A financing for Cellino Biotech to autonomize stem cell therapy manufacturing
|
25 January 2022 |
Bayer and Mammoth Biosciences to collaborate on novel gene editing technolog
|
10 January 2022 |
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
|
10 August 2021 |
Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson's disease
|
08 June 2021 |
Bayer to manufacture mRNA vaccine in Germany
|
01 February 2021 |
Bayer transforms pharma business through breakthrough innovation in healthcare
|
14 January 2021 |
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
|
07 January 2021 |